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Abstract
Background: The Expected Value of Sample Information (EVSI) de-
termines the economic value of any future study with a specific design
aimed at reducing uncertainty in a health economic model. This has po-
tential as a tool for trial design; the cost and value of different designs
could be compared to find the trial with the greatest net benefit. However,
despite recent developments, EVSI analysis can be slow especially when
optimising over a large number of different designs. Methods: This paper
develops a method to reduce the computation time required to calculate
the EVSI across different sample sizes. Our method extends the moment
matching approach to EVSI estimation to optimise over different sample
sizes for the underlying trial with a similar computational cost to a single
EVSI estimate. This extension calculates posterior variances across the
alternative sample sizes and then uses Bayesian non-linear regression to
calculate the EVSI. Results: A health economic model developed to assess
the cost-effectiveness of interventions for chronic pain demonstrates that
this EVSI calculation method is fast and accurate for realistic models.
This example also highlights how different trial designs can be compared
using the EVSI. Conclusion: The proposed estimation method is fast and
accurate when calculating the EVSI across different sample sizes. This
will allow researchers to realise the potential of using the EVSI to de-
termine an economically optimal trial design for reducing uncertainty in
health economic models. Limitations: Our method relies on some ad-
ditional simulation, which can be expensive in models with very large
computational cost.
1 Introduction
The Expected Value of Sample Information (EVSI) [32] quantifies the expected
economic benefit of a data collection exercise with a given design. In gen-
eral, new data update information about the parameters underlying a health
economic model. This, in turn, updates information about the optimal treat-
ment or intervention and thereby reduces the possibility of funding an inefficient
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treatment, which may only have been deemed to be economically efficient due
to deficiencies in the current information.
The EVSI is a Value of Information (VoI) measure [22] used to analyse the
potential benefit of resolving uncertainty in a decision model. Amongst these
measures, the EVSI has the greatest potential to inform research decisions as it
quantifies the economic benefit of a specific study. This value can be compared
directly with the cost of the trial to determine whether a study should go ahead,
making the EVSI an important tool for decision makers and funders looking to
efficiently allocate research and development resources [26].
In addition to this, the EVSI has potential as a tool for trial design when it
is calculated for a number of different designs [40]. The trial with the largest
“net” economic value is then selected, by considering the cost of implemen-
tation alongside the EVSI. Using the EVSI in this setting ensures that the
data collected in the study are sufficient to reliably inform the health economic
model. Therefore, following the study, the cost-effectiveness of the different
treatments can be correctly assessed, which is a key requirement within pub-
licly funded health systems where treatments/interventions must demonstrate
cost-effectiveness over competitors [11, 13, 9, 12]. However, the computational
time required to calculate the EVSI based on realistic health economic models
has restricted its practical applications [33] meaning that studies are normally
designed using power calculations to determine an appropriate sample size.
With the exception of cases in which the health economic model conforms
to certain conditions [1, 39, 7], traditionally, the EVSI has been estimated using
computationally intensive nested Monte Carlo simulations [28, 2, 31, 38]. How-
ever, recent methodological advances have employed various methods to avoid
the need for full nested simulations, irrespective of the underlying model struc-
ture [35, 27, 25, 21, 24]. In theory, these methods have unlocked the power of
EVSI analysis for use in research prioritisation and study design.
Unfortunately, using the EVSI as a tool to identify the optimal study design
still requires calculations to be made across a number of different possible data
collection exercises, e.g. changing the sample size or the main outcome. In this
paper, we present an extension to the “moment matching” estimation method
[21, 17] that calculates the EVSI across different sample sizes for the future
study with approximately the same computational cost as a single estimate.
Our extension uses Bayesian non-linear regression to estimate the EVSI
across different sample sizes, by incorporating prior information about the be-
haviour of EVSI. It also models uncertainty in the EVSI that arises from its
estimation using simulation. The resulting quantification of uncertainty in the
EVSI estimate allows funders to assess the accuracy of their research and de-
velopment decisions.
The moment matching method only requires that the health economic model
is based on a Bayesian model that incorporates the data arising from the study.
This requirement comes directly from the definition of the EVSI and imposes no
restrictions on the complexity of the health economic model or data collection
exercise used to calculate the EVSI. Additionally, this requirement allows EVSI
calculations to be undertaken whilst considering common trial issues such as
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missingness or loss to drop out in the data. Therefore, this extension to the
moment matching method can find the optimal sample size while taking into
account realistic assumptions about the study and the model.
To present this extension, we briefly introduce the EVSI in §2 and the stan-
dard moment matching method [20] in §3. Following this, we present a Bayesian
non-linear model that can be used to estimate the EVSI across different sample
sizes based on one simulation per sample size in §4. Finally, we then present
a practical implementation of this method using a real-life health economic
model developed to compare treatments for chronic pain [36]. We compare our
estimates with the computationally intensive nested Monte Carlo simulation
method to demonstrate its accuracy. We also explore how the EVSI can be
used as a tool for trial design by considering two alternative designs across a
range of sample sizes.
2 The Expected Value of Sample Information
The EVSI quantifies the economic benefit of reducing uncertainty in a health
economic model using a specific method for data collection. Therefore, we
first define a health economic model to compare treatments for a specific dis-
ease/health state. This is typically defined in terms of a large vector of param-
eters θ, used to describe the properties of the underlying disease, for example
survival probabilities, Quality of Life measures and health service costs. In a
Bayesian setting, a joint probability distribution p(θ) defines the current un-
certainty level in these parameters and is typically informed by a number of
different data sources such as clinical trials augmented by additional informa-
tion from the literature in a process known as Probabilistic Sensitivity Analysis
(PSA) [5]. The corresponding frequentist bootstrap approach to PSA typically
models each parameter in θ individually to represent the current level of uncer-
tainty in the model parameters.
In a health economic model, the value of each treatment is normally defined
using a “net benefit” function dependent on the model parameters, NBθt for t =
1, . . . , T possible interventions/alternatives. The probability distribution p(θ)
then induces a distribution for the net benefit for each treatment. Typically, we
consider that variation due to individual level response to treatments had been
marginalised out, so if the parameters were known exactly then the net benefit
of each treatment would also be known. The optimal treatment given current
evidence is then found by averaging out all uncertainty for each treatment,
NBt = Eθ
[
NBθt
]
, and then finding the most valuable treatment, maxtNBt.
However, the current uncertainty in the parameters may suggest that the
incorrect treatment is optimal. This is because additional information gleaned
from a study would update the distribution of the model parameters which
would then update the distribution of the net benefit. This could change the
optimal treatment, indicating that the current information is not sufficient to
make the correct treatment recommendation, for example, additional side effects
could be observed when a new treatment is monitored for a longer period of time
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in a greater number of patients. In this case, the additional data have value
as patients are prevented from receiving an inefficient treatment and financial
resources are saved.
Formally, a study collects data, denoted X, which update the informa-
tion about the model parameters θ. This updating falls within the Bayesian
paradigm in which we consider p(θ) as the prior distribution for the model pa-
rameters. The sampling distribution for the data is combined with the prior to
determine a posterior for model parameters p(θ |X). The net benefit for each
treatment is calculated as a function of θ and the optimal treatment found by
maximising the posterior expected net benefit. The economic value of the study
is then the difference between the expected net benefit of the optimal treatment
with the updated information and the current information.
However, as the EVSI is calculated before the data have been collected, the
study outcome is unknown. Therefore, we consider a distribution for all the
possible datasets that could arise from the study and calculate the value of
every study outcome. The EVSI is the average study value over all the possible
future datasets. Mathematically, this is expressed as
EVSI = EX
[
max
t
{
Eθ|X
[
NBθt
]}]
−max
t
{
Eθ
[
NBθt
]}
, (1)
where the distribution of X should be consistent with how the data would be
analysed if the study were run. This means that we define a sampling distribu-
tion for the data given the parameters, p(X | θ), which is combined with p(θ)
to give the distribution of all the possible samples.
It is almost impossible to calculate the EVSI analytically, so in practical
scenarios it is estimated using simulations. Computationally, the challenge is
to compute the inner “posterior” expectation for the net benefit of each treat-
ment for each possible study, Eθ|X
[
NBθt
]
for t = 1, . . . , T . If this posterior
expectation is available in closed form, then estimating the EVSI by simulation
requires little computational effort as we simply require a large number of sim-
ulated study outcomes. However, in practical models this analytic expectation
will rarely be available so alternative methods must be used. The most general
method is to estimate the inner expectation using simulations from the poste-
rior of θ, conditional on each of the simulated study outcomes. This means that
the simulations required to estimate the posterior expectation are nested within
the simulations of possible study outcomes, leading to a nested Monte Carlo
simulation method with relatively high computational cost as typically around
1000 simulated study outcomes are used.
Our “moment matching” method also estimates the EVSI using simulation
but circumvents the need for full nested Monte Carlo simulation by estimat-
ing the “posterior” expectation across all the potential samples using a small
number, between 30-50, of simulated future datasets [21].
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3 The moment matching method
Thus far, we have presented the EVSI for health economic models that compare
T treatments. However, for simplicity, we restrict ourselves to the dual-decision
setting, i.e. t = 1, 2, before returning to the general setting in the supplementary
material. To simplify the calculations still further, we work directly with the
incremental net benefit, i.e. INBθ = NBθ1 − NBθ2 . The incremental net benefit
contains all the information required to make a decision between treatment 1
and treatment 2. Specifically, treatment 1 is optimal if the expected incremental
net benefit is positive and treatment 2 is optimal otherwise. Therefore, to
calculate the EVSI, we must estimate the posterior expectation of INBθ across
the different study outcomes, which we denote µX = Eθ|X
[
INBθ
]
. To further
clarify the moment matching method, a full list of notation is given in Table 1
at the end of §4.
3.1 Estimating the distribution of µX using moment match-
ing
Formally, the moment matching method is used to estimate the distribution
of µX , denoted p(µX), which is induced by the distribution of the potential
datasets X. Specifically, the moment matching method exploits the similarity
between p
(
µX
)
and the distribution of a specific function of INBθ to reduce the
required number of nested Monte Carlo simulations [21]. To find this function
of INBθ, we assume that the future sample only directly updates a subset φ of
the model parameters θ; for example, a clinical trial would inform the primary
clinical outcome but is unlikely to give information on the societal costs of the
disease. The distribution of µX is then expected to be similar to the distribution
of
INBφ = Eθ|φ
[
INBθ
]
, (2)
except that the variance of µX is smaller than the variance of INBφ [21]. In
practice, therefore, the moment matching method approximates p
(
µX
)
by lin-
early rescaling the simulated values of INBφ to reduce their variance so it is
equal to the variance of µX , denoted σ2X , which must also be estimated.
3.2 Estimating simulated values of INBφ
Simulated values of INBφ, denoted INBφs for s = 1, . . . , S, can be found in a
computationally efficient manner using methods developed for the calculation of
the Expected Value of Partial Perfect Information (EVPPI), which is based on
the expectation in equation (2). The main reason for using these methods is that
the EVPPI is an upper bound for the EVSI and is much simpler to compute.
As the EVSI must be large to indicate that a study is worthwhile, a study with
a small EVPPI, the upper limit of the value, will not be economically viable,
irrespective of design. Therefore, the EVPPI should always be calculated before
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the EVSI as a screening procedure [37] implying that INBφs should be available
before attempting to calculate the EVSI.
In most health economic models, an EVPPI calculation method based on
non-parametric regression is fast and accurate [20]. This uses regression to
estimate INBφ and is easily generalisable implying that general purpose software
[4] or stand alone functions [34] can estimate INBφ based solely on the PSA
simulations for φ and INBθ.
3.3 Estimating the variance of µX
The variance of µX , denoted σ2X , is estimated using the law of total variance
σ2X = VarX
[
Eθ|X
[
INBθ
]]
= Var
[
INBθ
]
− EX
[
Varθ|X
[
INBθ
]]
.
Firstly, the variance of INBθ, denoted σ2, can be estimated by the sample
variance of the PSA simulations of INBθ. Therefore, σ2X can be estimated
by determining the expected posterior variance of the incremental net benefit,
where the expectation is taken across the different potential datasets.
This expected posterior variance for INBθ can actually be estimated accu-
rately using a small number Q of nested simulations, with 30 < Q < 50, pro-
vided the nested samples are undertaken using a specific method, demonstrated
pictorially in Figure 1. This method begins with a standard PSA procedure,
represented in the left-hand panel in Figure 1 with S = 1000. In this procedure,
the parameters θ are simulated from p(θ) and then used to calculate the INBθ.
To proceed, we select the columns of the PSA matrix that contain the sim-
ulations for the parameters of interest φ. These columns are then ordered sep-
arately, represented by the middle panel in Figure 1. Finally, Q equally spaced
values are selected from these ordered lists to find the sample quantiles for each
element of φ. For each row of sample quantiles, φq, q = 1, . . . , Q, one sample
is simulated from p(X | φq), indicated by Xq, represented in the right hand
graphic. To estimate the expected posterior variance, each of these Q simulated
future samples, Xq, is used to update the posterior for the model parameters
p(θ | Xq) and thereby induces a posterior distribution for INBθ. In turn, this
is estimated using simulations, with which the posterior variance of INBθ, de-
noted σ2q , can be estimated for each future sample. Finally, the variance σ
2
X is
estimated by taking the average of the σ2q and subtracting this from σ
2;
σ2X = σ
2 − 1
Q
Q∑
q=1
σ2q .
3.4 Linear rescaling of INBφ to estimate the EVSI
Once σ2X has been estimated, the EVSI is calculated by rescaling INB
φs so
the variance of these simulated values is equal to σ2X . This is achieved by first
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θ1 θ2 θ3 . . . INBθ φ1 φ2 φ3 . . . INBφ φ1 φ2 φ3 → Xq
p(X | φ)
Figure 1: A pictorial representation of the simulation method used to estimate
the posterior variances σ2q for q = 1, . . . , Q. The left-hand panel represents the
standard PSA procedure, darker lines represent large values for the variable of
interest while lighter lines represent smaller values. The middle panel selects
the parameters of interest and reorders them smallest to largest. The right-
hand panel demonstrates that the quantiles for φ should be selected and then
a dataset should be simulated for each row.
calculating
ηXs =
INBφs − µ√
σ2φ
√
σ2X + µ, (3)
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where µ = E
[
INBθ
]
is estimated using the PSA simulations of INBθ and σ2φ is
the sample variance of INBφs , s = 1, . . . , S. The EVSI is then calculated from
ηXs by taking
EVSI =
1
S
S∑
s=1
max
{
0, ηXs
}−max {0, µ} . (4)
4 Calculating the EVSI for different sample sizes
A key aspect of designing a trial is to determine the number of patients that
should be enrolled. Typically, this is achieved using power calculations that
determine the trial sample size by ensuring that a hypothesis test concerning
the primary outcome has desirable properties [10]. To use the EVSI alongside, or
as an alternative to, these power calculations requires that the EVSI is estimated
across different sample sizes. For example, financial or clinical constraints limit
the possible sample sizes for a trial and then the EVSI must be estimated on
a grid of R sample sizes between these limits, N = (Nmin = N1, N2, . . . , NR =
Nmax).
Using the moment matching method to estimate the EVSI across these sam-
ple sizes would require R×Q posterior updates. This quickly becomes infeasible
as R, the number of sample sizes considered, increases. Therefore, this section
extends the moment matching method to estimate the EVSI across different
sample sizes by setting R = Q and only requiring one posterior update per
sample size. This reduces the required number of posterior updates from R×Q
to Q — the same as the standard method.
For this extension, each potential data set Xq is simulated conditional on
the vector (φq, Nq), rather than solely on (φq), represented pictorially in Figure
2. Once these datasets X1, . . . ,XQ, with different sample sizes, have been
simulated the extended moment matching method proceeds in the standard
method; each dataset updates the distribution of the model parameters and
then the posterior variance of the incremental net benefit is calculated, giving
σ2q for q = 1, . . . , Q.
However, to then estimate the EVSI across sample size, we develop an alter-
native strategy to estimate σ2X from (σ
2
1 , . . . , σ
2
Q). This is because we are now
interested in estimating σ2X(N), i.e. the variance of the expected posterior mean
µX(N) for different samples of size N . In a similar manner to Mu¨ller and Parmi-
giani [29], we use regression methods to estimate a function f(N) = σ2X(N),
using σ2q . The estimated values σ
2
q are generated conditional on a specific future
dataset Xq, of size Nq. This dataset represents one possible future, which is
subject to variation due to random sampling and dependence on the specific
value of φq. In the standard moment matching method, we marginalise out this
dependence on the specific φq value by taking the mean of σ
2
q . However, in this
extended setting, we use regression to marginalise out this dependence across
the different sample sizes Nq. Therefore, we use the values of σ
2
q , obtained by
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simulation, to estimate the function f(N) as
σ2 − σ2q = f(Nq) + εq,
where εq is an error term that captures variation in σ
2
q due to using simulated
datasets with sample size Nq.
4.1 A Bayesian non-linear model
To estimate σ2X(N), we define a Bayesian non-linear model which allows us to
encode our knowledge about the underlying behaviour of σ2X(N). It also allows
us to propagate uncertainty from our estimation procedure into the EVSI esti-
mate so researchers can assess the accuracy of the moment matching procedure.
Our model is defined by assuming a functional form for the regression func-
tion,
f(N) = σ2φ
N
N + h
,
where σ2φ = Var
[
INBφ
]
and h is a parameter to be estimated, and by modelling
the residual error as a normal distribution centred on 0, εq ∼ N(0, σ2ε) for
q = 1, . . . , Q. This functional form for f(N) reflects the underlying knowledge
about σ2X(N). Specifically, we know that σ
2
X(N) increases as N increases and
f(N) is an increasing function. In addition to this, a study with an infinite
sample size would be equivalent to gaining perfect information about the model
parameters φ. This means that µX(N) tends to INBφ as N → ∞, so for
an infinite sample size we have σ2X(∞) = σ2φ. Finally, the functional form
of f(N) is the exact relationship between N and σ2X(N) in normal-normal
conjugate settings with only one underlying model parameter. So, while realistic
health-economic models are not based on normal-normal conjugate models and
have multiple model parameters, this function is approximately correct in many
settings.
To define the full Bayesian model, priors must be defined for h, the regression
parameter, and σ2ε , the residual variance. Throughout, we have used a non-
central half-Cauchy prior for σε, as suggested by Gelman [15], with parameters
dependent on the data. This is because the scale of σ2q changes significantly
across health economic models. Therefore, the prior mean is set to the standard
deviation of σ2q divided by 2 and the prior variance to the standard deviation of
σ2q . Finally, a data dependent normal prior, truncated at 0, is set for h with the
prior mean and variance set to Nmax2 and 200×Nmax respectively, giving vague
priors for h and σ2ε .
4.2 Calculating the EVSI for different sample sizes
To calculate the EVSI, we fit this non-linear model using the estimated poste-
rior variances from the health economic model σ2q . Fitting this model requires
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Markov Chain Monte Carlo methods to estimate the posterior for h by simula-
tion. The posterior distribution for σ2X(N), irrespective of whether N is in N ,
can be estimated by calculating
f(N) = σ2X(N) = σ
2
φ
N
N + h
for each posterior simulation for h. In theory, each simulation from the posterior
distribution of σ2X(N) can be used to rescale INB
φs , equation (3), and estimate
the EVSI using equation (4).
However, this process is computationally intensive if there is a large number
of posterior simulations for h. Therefore, it is more efficient to calculate the
EVSI for a small number of samples from the posterior of σ2X(N). We advise
that the posterior of σ2X(N) is summarised by finding credible intervals for a
small number of credible levels. The EVSI is then calculated for each estimated
variance in this low-dimensional summary. For example, in §5, the posteriors
for σ2X(N) are summarised using the median and the 75% and 95% credible
intervals. Note that, the values calculated using this method are not the poste-
rior credible intervals for the EVSI as the relationship between the σ2X(N) and
the EVSI is highly non-linear. Code to calculate the EVSI using this method is
provided in the supplimentary material.
4.3 Practical Considerations
The first practical consideration is that the function f(N) changes quickly for
small sample sizes, meaning that smaller values of N sizes give more informa-
tion about h. Therefore, we suggest that more future samples Xq are generated
for small sample sizes. Practically, this is achieved by choosing Nq values that
are evenly spaced on the square root scale between Nmin and Nmax. This has a
computational advantage as Bayesian updating typically requires more comput-
ing time to estimate the posterior distribution conditional on larger datasets.
Therefore, choosing Nq in this manner improves fit and reduces computation
time.
Next, this non-linear regression method requires that φq and Nq are un-
correlated. This is because there is normally a relationship between σ2X(N)
and φ, through the simulated dataset Xq. If φq and Nq are also correlated
then this can mask/inflate the relationship between σ2X(N) and N . Thus far,
φq has been defined as a row containing the sample quantiles for each element
of φ and Nq as increasing values between Nmin and Nmax. This specification
naturally induces a correlation between φq and Nq which can lead to biased re-
sults. Therefore, it is suggested that each element of φq is randomly reordered
separately before generating Xq. Reordering each φq vector separately also im-
proves accuracy by inducing a greater variation in the Xq samples. Therefore,
the simulation method for Xq is represented in Figure 2, where the quantiles
for φ are reordered separately for each column and then combined with ordered
sample sizes, spaced on the square root scales, to generate one potential sample
Xq for each sample size.
10
Notation Definition
p(·) The distribution of a random variable.
θ The underlying model parameters for the health economic model.
φ The model parameters that are informed by the trial under consideration.
S The number of PSA simulations taken from p(θ).
X The potential data arising from the future study.
INBθ The incremental net benefit, where uncertainty is induced by the model parameters.
INBφ The conditional expectation of the incremental net benefit conditional on φ.
µ The expected value of INBθ across all values of θ.
σ2 The variance of INBθ.
σ2φ The variance of INB
φ.
µX The posterior expectation of INBθ conditional on the potential datasets.
µX(N) The posterior expectation of the incremental net benefit across potential future datasets
with a given sample size of N .
σ2X The variance of µ
X .
σ2X(N) The variance of µ
X(N) for potential datasets of a given sample size N .
Q The number of nested simulations taken to estimate the EVSI using moment matching.
φq The q-th row of a matrix that contains the quantiles of the PSA simulations for φ for
q = 1, . . . , Q.
Nq The q-th element in a vector of sample sizes between the minimum and maximum sample
sizes for q = 1, . . . , Q.
Xq The q-th simulated potential dataset for q = 1, . . . , Q. Datasets are simulated conditional
on φq only in the standard method and on the pair (φq, Nq) in the extension.
σ2q The posterior variance of the incremental net benefit conditional on the dataset Xq for
q = 1, . . . , Q.
ηXs The simulated values of INB
φ that have been rescaled to approximate simulations from the
distribution of µX . The subscript s defines the s-th simulated value for s = 1, . . . , S.
σ2ε The residual variance for Bayesian non-linear regression used to estimate σ
2
X(N).
Table 1: A list of the key notation used to demonstrate the moment matching
method and the extension using non-linear regression.
Finally, as this EVSI estimation method is based on regression, its accuracy
can be checked using standard model checking procedures such as residual or qq-
plots. Specifically, the residuals should exhibit no clear unmodelled structure,
as in standard regression modelling.
5 Implementation of the Extended Moment Match-
ing Method
This section implements our extended moment matching method to calculate
the EVSI across different sample sizes. The supplementary material demon-
strates that our method is in line with other EVSI calculation methods [27, 35]
using a hypothetical health economic model developed in [6]. To demonstrate
11
φ1 φ2 φ3 N Xq→
p(X | φ, N)
Figure 2: A pictorial representation of the sampling procedure for the future
samples in the extended moment matching method. As in Figure 1, darker lines
represent higher values for the parameters.
the power of the extended moment matching method, we determine the optimal
trial design for a practical health-economic model that evaluates different treat-
ments for chronic pain [36]. In this analysis, we compare our method with the
nested Monte Carlo simulation method to demonstrate accuracy and compare
computation time.
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5.1 A Health Economic Model for Chronic Pain
Sullivan et al. [36] developed a cost-effectiveness model for evaluating treatment
options for chronic pain. The model is based on a Markov structure with 10
states, where each state has an associated utility score and cost. The disease
progression for chronic pain is as follows: the treatment is administered and a
patient can either experience adverse effects of the treatment (AE) or not. The
patient can then withdraw from treatment, either due to the AE or otherwise.
They can then continue to another treatment option or withdraw completely
from treatment. After the second line of treatment, they either have subsequent
treatment or discontinue (these are absorbing states).
In the standard model, a patient can either be offered morphine or a inno-
vative treatment in the first line of treatment. If they withdraw and receive a
second treatment, they are offered oxycodone, meaning the only difference be-
tween the two treatment arms occurs when the first treatment is administered.
The innovative treatment is more effective and reduces the probability of AE
but is more expensive.
The model uses a willingness-to-pay of £20 000, the threshold under which
treatments are likely to receive a recommendation in the UK [30]. For a more
in-depth presentation of all the model parameters, see [36]. The PSA is based
on gamma distributions for costs and beta distributions for probabilities and
utilities. The parameters for these distributions are chosen such that the mean
is informed by a literature review and the standard deviation is taken as 10% of
the underlying mean estimate. For illustrative purposes, the per person lifetime
EVSI is considered throughout this section. This assumes a discount factor of
0.03 over 15 years of the treatment being available.
5.2 Analysis for the Chronic Pain Example
A full VoI analysis, as set out by Tuffaha et al. [37], is undertaken for the chronic
pain model. To begin, 100 000 simulations are taken from the prior for the model
parameters. These are then fed through the Markov model to give 100 000
simulations for the incremental net benefit. Calculating the EVPPI [8, 35, 19]
based on these simulations indicated that the most valuable parameters are
those relating to the utility of the different health states for the first line of
treatment. Specifically, the utility of not having any AE from the treatment
and withdrawing from the treatment without experiencing AE.
In response to this, we designed an experiment to learn about the utility of
these two health states, which, if known with certainty, would account for about
79% of the uncertainty in the decision. Questionnaires are a standard method for
determining QALYs and therefore we designed a trial in which questionnaires are
sent to N participants. We assume, in a simplistic manner, that a participant is
sent the questionnaire if they withdrew from the first treatment without any AE.
They are then questioned about both health states, which they can accurately
recall. This means that each questionnaire directly updates information about
both these key utility parameters.
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Responses from these questionnaires will be translated into a utility score
for each health state. These utility scores are modelled as independent beta
distributions with their means conditional on the utility of interest, the utility
of not having AE and withdrawing without AE, and standard deviations equal
to 0.3 and 0.31 respectively [23]. We consider sample sizes between Nmin = 10
and Nmax = 150. It is then assumed that only a proportion of the questionnaires
are returned, leading to missingness in the data.
Within this context, two different designs are considered based on the results
of a trial investigating whether financial incentives improve the rate of return of
questionnaires in clinical trials [14]; we assume that the questionnaire could be
accompanied by a £5 incentive to complete. This incentive study demonstrated
that sending the financial reward improved response rate from 68.7% to 75.7%
while increasing the cost from £4.64 to £9.35. The difference in cost is not
equal to the incentive because non-respondents are chased up by telephone,
which costs staff time and other resources and sending the reward reduces the
number of chase-up calls needed.
Therefore, the EVSI will be used to answer two key questions regarding the
design of this study; firstly, should the incentive be used? and secondly, how
many questionnaires should be sent? The EVSI is estimated for both response
rates using Q = 50 with 10 000 posterior simulations fed through the Markov
model and used to estimate σ2q for each q = 1, . . . , Q. The EVSI results using the
moment matching method are compared with nested Monte Carlo simulations
for sample sizes 10, 25, 50, 100 and 150. These nested MC estimators were
calculated using 100 000 PSA simulations to generate the future samples and
then 100 000 posterior simulations per PSA simulation. So, 1 billion simulations
were used for each sample size to estimate the EVSI using nested Monte Carlo
simulations as opposed to 500 000 simulations for our novel method.
5.3 Results for the Chronic Pain Model
Figure 3 displays the net economic value for both designs; the grey curves are
the economic value of the study with no incentive and the black curves are the
value of the incentive study from the moment matching method. The economic
value of a study is the difference between the EVSI and its cost, from [14].
Clearly, the no incentive study is economically more valuable. This is because
the reduced missingness in the questionnaire responses is not valuable enough
to warrant the cost of the incentive. Note, however, that the dominance of
the no incentive study is uncertain for very small sample sizes as the EVSI
“distributions” overlap.
Figure 3 also shows the nested Monte Carlo estimates for the economic study
value; the black crosses give the value for the no incentive study and the grey
crosses for the incentive study. Using these estimates, we demonstrate that the
moment matching method with non-linear regression is in line with the nested
Monte Carlo simulation. This means that, in this example, our novel EVSI
calculation method is accurate, despite the non-linear and non-Gaussian model
structure of the health economic model, and significantly reduces the required
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number of simulations for this analysis.
20 40 60 80 100 120 140
−
60
0
−
40
0
−
20
0
0
20
0
40
0
60
0
Sample Size of  XN
Ec
on
om
ic
 v
a
lu
e
Figure 3: The economic value (difference between EVSI and the cost of under-
taking the study) of the two alternative questionnaire collection strategies for
different sample sizes in the chronic pain example. The grey curves indicate the
potential value of the study without incentives and the black curves the value of
the study with incentives estimated using the moment matching method. The
black crosses represent the no-incentive Monte Carlo simulation estimates and
the grey crosses represent the same estimates for the incentive study.
Analysing the economic value for different sample sizes determines that the
optimal sample size in terms of economic benefit is 16 for the incentive study
and 27 for the no incentive study. Therefore, overall, the optimal study is a no
incentive study with 27 participants; the information gained from any additional
patients is not worth the cost of sending the questionnaire and chasing up the
non-respondents.
The total computational time to calculate the EVSI for both studies using
our novel calculation method is 331 seconds or around 5 and a half minutes on
a standard desktop computer with a Intel i7 Pro processor using R version 3.2.1.
This includes fitting the regression model to calculate the EVSI across different
sample sizes for both study designs, which is around 5 seconds per study. On
the other hand, the nested Monte Carlo simulations required between between
15
7 and 68 days for each EVSI estimate, with a total computation time of around
311 days for all 10 estimates.
6 Discussion
The EVSI has frequently been touted as a method for study design, includ-
ing determining the optimal study size. However, its application in this area
has been limited by the computational time required to obtain EVSI estimates
across different designs. Several approximation methods have reduced the com-
putational time per EVSI estimate to allow for this type of analysis. However,
even with these calculation methods, the computational time increases linearly
with the number of sample sizes considered.
Therefore, in this paper we present an extension to the moment matching
method for EVSI calculation [21] that performs the analysis over different sample
sizes with a minimal fixed additional computational cost. This implies that the
cost of estimating the EVSI for a single design is approximately equal to the
evaluation of the EVSI across different sample sizes. This method augments the
moment matching method with Bayesian non-linear regression. This estimates
the EVSI by calculating the posterior variance of the incremental net benefit
for around 50 different sample sizes. In general, the posterior variance is easy
to calculate provided a sampling distribution can be defined for the data and a
Bayesian model can be specified for the model parameters.
The augmented moment matching method determined the optimal study de-
sign to update the information underpinning a real-life health economic model
that evaluates interventions for the treatment of chronic pain. We also demon-
strated that our novel method accurately estimates the EVSI by comparing with
nested Monte Carlo simulations.
This method allows researchers to determine the optimal sample size for their
trials using EVSI. The minimal computational time also allows them to compare
a number of other design features. Finally, this method is implemented in the R
package EVSI [16] making this method relatively simple to implement for general
health economic models. The EVSI package also extends the methodology to
calculate the EVSI across different net benefit functions at a minimal extra cost.
Finally, the package also includes a suite of graphics and an online tool so EVSI
results can be presented to key stakeholders [18].
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A Multi-Decision Models
In general, there is little theoretical difference between the moment matching
method for multi-decision models and the moment matching method in the dual-
decision setting that has been presented in the paper. The method still proceeds
by calculating the posterior variance of the incremental net benefit across dif-
ferent potential simulated datasets. These calculated variances are then used to
rescale the expectation of INBφ. However, as we have more than two decisions,
the incremental net benefit is defined in a slightly different manner.
In the multi-decision setting, we choose a reference treatment, say T , and
then calculate the incremental net benefit of all the treatments with respect to
this reference treatment, i.e.
INBθt = NB
θ
t −NBθT .
Therefore, the incremental net benefit INBθ can be thought of as a multivariate
random vector:
INBθ =

INBθ1
INBθ2
...
INBθT−1
 . (5)
This means that the variance of INBθ is a variance-covariance matrix rather
than a scalar value and so we denote it Σθ. If the EVSI calculation is being
performed in R, then the variance-covariance matrix is computed when using the
var() function so this extension adds no complexity to the moment matching
procedure.
To find INBφ using non-parametric regression, a regression curve should be
fitted for incremental net benefit to give a multivariate vector:
INBφ =

INBφ1
INBφ2
...
INBφT−1
 , (6)
with a variance covariance matrix denoted Σφ. The standard moment matching
method would proceed as normal, i.e. for each potential sample Xq, we would
calculate the variance of INBθ, the only difference in the multi-decision setting
is that the variance is a variance-covariance matrix which we denote Σq.
In the multi-decision setting, as before, we are aiming to estimate the distri-
bution of µX = Eθ|X
(
INBθ
)
. However, this is now a multivariate distribution
with a variance-covariance matrix, denoted ΣX . Each element of this matrix,
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σijX for i = 1, . . . , T − 1 and j = 1, . . . , T − 1, is calculated in a similar manner
as the dual decision setting,
σijX = σ
ij
θ −
1
Q
Q∑
q=1
σijq ,
where σijθ is the element of the i-th row and j-th column of the Σθ matrix and
σijq is the same element of the Σq matrices. This is therefore, the same formula
as the dual-decision setting but separately for each element of the variance-
covariance matrix.
To rescale the distribution of INBφ, we use the same formula as in the
standard method, but, rather than dividing by the standard deviation we must
multiply by the inverse matrix square root. Matrix square roots and inverses
are well-defined and can easily be found in R using the expm package. Therefore,
to rescale the simulated PSA vectors for INBφ, denoted INBφs , s = 1, . . . , S,
we use the following formula:
ηXs = (INB
φs − µ)Σ− 12φ Σ
1
2
X + µ.
The EVSI is then calculated by taking the row-wise maximum of each of the
ηXs vectors and 0 and then taking the mean of these maximums.
Using non-linear regression to calculate the EVSI in multi-decision problems
involves an extension to the standard method. The non-linear model defined in
the main paper is a scalar function and we must estimate a variance-covariance
matrix across different sample sizes. Therefore, we must extend this regres-
sion model to a matrix function. In practice, we suggest that the non-linear
regression function is extended by fitting the non-linear model from main paper
f(N) = σ2φ
N
N + h
separately for each unique element of the variance-covariance matrix. Essen-
tially, this involves estimating the element in the i-th row and j-th column of
the variance matrix ΣX(N) for a sample size N , denoted σ
ij
X(N) as
f ij(N) = σijX(N) = σ
ij
φ
N
N + hij
,
where σijφ is the i-th, j-th element of the Σφ matrix. It is possible to demon-
strate in a decision model with three treatment options that these functions
approximately estimate the variance of both incremental net benefits and their
covariance in normal-normal conjugate settings.
As the covariance matrix is symmetric, f ij(N) = f ji(N) and so we fit
(T − 1)T
2
regression models separately to calculate the EVSI across different sample sizes,
where T is the number of possible interventions. Each curve will produce an
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estimate for the hij parameter and these distributions can be combined to find
the posterior distribution of the variance-covariance matrix for ΣX(N) for each
sample size N under consideration.
Finally, recall that the distribution of variance-covariance matrix for σ2X(N)
was approximated by a low-dimensional summary of the distribution of the
posterior distribution for h in the main paper. Clearly, this is more challenging
when multiple curves are being fitted. Nonetheless, we suggest that hij posterior
is summarised by finding a low-dimensional summary and then these are then
used to create a small number of variance-covariance matrices. These matrices
are used to rescale are then used to rescale INBφ using the formula above.
The EVSI is finally calculated with the same method in the standard moment
matching method. This method does not give credible intervals for the EVSI
but computationally efficient way to calculate a low-dimensional summary of
the possible EVSI values.
B Calculating the EVSI using Moment Match-
ing for the Brennan and Kharroubi Example
This model has frequently been used to assess calculation methods for the EVSI.
It was first developed by Brennan and Kharroubi [6] and modified by Menzies
[27] to compare two treatments used to treat a hypothetical disease. For each
drug, a patient can respond to the treatment, experience side effects or visit
hospital for a certain length of time. A utility value is assigned to each of these
possible outcomes and costs are associated with the drugs and hospital stays.
All the parameters are assumed to be normal with the mean and standard
deviation given in Table 2. The studies are also assumed to have normal dis-
tributions, with the standard deviations given in Table 2. In this example, it
is assumed that θ5, θ7, θ14 and θ16 are correlated with correlation coefficient 0.6
and the parameters θ6 and θ15 are also correlated with a correlation coefficient
0.6 and independent of the other set of parameters.
The net benefits for each treatment are calculated as a deterministic function
of these parameters
NB1 = λ(θ5θ6θ7 + θ8θ9θ10)− (θ1 + θ2θ3θ4),
NB2 = λ(θ14θ15θ16 + θ17θ18θ19)− (θ11 + θ12θ13θ4),
with λ = $100 000. Five alternative data collection exercises are proposed by
Menzies and are also considered in this exploration:
1. A clinical trial collecting information on the probability that a patient
responds to the two treatment options which informs parameters θ5 and
θ14.
2. A study looking at the utility improvement for responding to the different
treatments which informs parameters θ6 and θ15.
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Mean Standard Deviation (SD) Data SD
Parameter t = 0 t = 0 t = 0 t = 1 t = 0 t = 1
Drug Cost (θ1, θ11) $10 000 $15 000 $10 $10 - -
Probability of Hospitalisation (θ2, θ12) 0.1 0.08 0.02 0.02 - -
Days in Hospital (θ3, θ13) 5.2 6.1 1 1 - -
Hospital Cost per Day (θ4) $4 000 $4 000 $2 000 $2 000 - -
Probability of Responding (θ5, θ14) 0.7 0.8 0.1 0.1 0.2 0.2
Utility Change due to Response (θ6, θ15) 0.3 0.3 0.1 0.05 0.2 0.2
Duration of Response (years) (θ7, θ16) 3 3 0.5 1 1 2
Probability of Side Effects (θ8, θ17) 0.25 0.2 0.1 0.05 - -
Utility Change due to Side Effects (θ9, θ18) -0.1 -0.1 0.02 0.02 - -
Duration of Side Effects (years) (θ10, θ19) 0.5 0.5 0.2 0.2 - -
Table 2: The parameters for the Brennan and Kharroubi example. The mean
and standard deviations for the distributions of the parameters is also given,
along with the standard deviation of the data collection exercise aimed at re-
ducing uncertainty in that parameter
3. A study investigating the duration of response to the therapy (for those
who do respond), informing parameters θ7 and θ16.
4. A study combining the first two studies, i.e. informing θ5, θ6, θ14 and θ15.
5. A study combining all the previous studies and therefore informing θ5, θ6, θ7, θ14, θ15
and θ16.
B.1 Analysis for the BK example
To estimate the EVSI for different sample sizes using the moment matching
method, the PSA distribution for the incremental net benefit is estimated using
1 million simulations from the parameter distributions. This implies that σ2
and µ, the variance and mean of the incremental net benefit respectively, are
estimated using this full sample. INBφ are also found using these 1 million
simulations, expect for exercise 5 which is based on 6 underlying parameters
meaning that the computational demands of estimating INBφ was too high.
These fitted values are, therefore, based on 20 000 simulations and obtained
using the R package BCEA [3, 4].
In line with Menzies [27], sample sizes between Nmin = 10 and Nmax = 200
are considered for each of the different exercises outlined above. Throughout the
analysis, we set Q = 50 which implies that 10 000 simulations are taken from
50 different posterior distributions to calculate the variance of the posterior
incremental net benefit for 50 different sample sizes. The distribution for the
EVSI is then determined using the method described in §4.2 in the main paper.
The results determined using our method are compared with the nested
Monte Carlo approach for calculating the EVSI and Menzies’ approach which
also reweights the PSA simulations for the INB but with an alternative method.
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These results are taken directly from Menzies [27] and are the most accurate
estimates available. The conventional approach required 1 billion model evalua-
tions per sample size compared with 500 000 model evaluations for the moment
matching method to estimate the EVSI across the different sample sizes.
B.2 Results for the BK example
Figure 4 shows the EVSI estimates for the BK example. The solid line gives
the EVSI calculated with the median of the posterior distribution of σ2X(N),
whereas the dashed line is the 75% credible interval and the dotted line the 95%
credible interval. The EVSI estimates from the nested Monte Carlo estimator
and the Menzies estimator are given by the red dots and the blue crosses respec-
tively. The nested Monte Carlo estimator (representative of the “true” EVSI)
is within the 95% credible interval for all exercises except exercise 5 (bottom),
where the EVSI is slightly over estimated for small values of N . This small
over-estimation may be due to the inaccuracies introduced by estimating INBφ
using only 20 000 observations, as opposed to the full PSA simulation used for
the other examples.
Figure 4 demonstrates that the EVSI is estimated with more relative pre-
cision as the EVSI estimate increases. This is because, for small values of the
EVSI, the difference between σ2q and σ
2 is small and the estimate of the two
variances needs to be very accurate in order to estimate the difference. There-
fore, this method for the EVSI calculation should be reserved for situations
where the underlying parameters have significant value. If the EVSI estimate is
too variable to aid decision making, as seen by the confidence bands, then more
simulation should be undertaken. In general, extra simulations should be gained
by increasing Q, provided the number of posterior simulations is sufficient to
characterise the distribution of the “posterior” incremental net benefit [17].
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C Non-Linear Regression Code
The following function calculates the EVSI across sample size using the non-
linear regression method presented in this paper. It also allows users to plot the
confidence bands for the EVSI as suggested in the paper when plot=TRUE.
calc.evsi.N<-function(INB.phi,INB.theta,sigma.q,N.q,plot=TRUE){
#INB.phi - The expectation of the INB conditional on phi, normally calculated
# using non-parametric regression
#INB.theta - The INB conditional on all model parameters
#sigma.q - A vector of "posterior" variances from simulations
#N.q - The N.q vector that contains the sample sizes for which the posterior
# variance is calculated
#plot - Logical. Should the graphic be plotted.
model.ab<-c(
"model{
#Prior for the non-linear regression parameter
h~dnorm(h.mean/2,h.tau) T(0.00000E+00, )
#Non-Linear Model
for(i in 1:Q){
sigma.X[i]~dnorm(mu[i],tau)
mu[i]<-sigma.phi*(N[i]/(N[i]+h))
}
#Prior for the residual variance
sigma ~ dt(sigma.mu, sigma.tau, 3) T(0.00000E+00, )
tau <- 1/sigma^2
}")
library(rjags)
#Writing Model Code into file
filein<-"model.txt"
writeLines(model.ab,filein)
#Calculate the variance for the different INB functions
sigma.INB<-var(INB.theta)
sigma.phi<-var(INB.phi)
Q<-length(N.q)
#Set up the data for the jags model
data.a.b<-list(
#Parameters for prior of residual variance
sigma.mu=sd(sigma.INB-sigma.q)/2,
sigma.tau=1/sd(sigma.INB-sigma.q),
#Parameters for prior for h
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h.mean=max(N.q),
h.tau=0.0005/max(N.q),
#Number of observed variances
Q=Q,
#Maximum variance of sigma.x^2
sigma.phi=sigma.phi,
#Data for the non-linear model
sigma.X=sigma.INB-sigma.q,
N=N.q)
#Run the jags model with the data
Model.JAGS<- rjags::jags.model(filein,data=data.a.b)
update(Model.JAGS,1000)
beta.ab <- rjags::coda.samples(Model.JAGS, c("h"), n.iter=3000,n.thin=1)
#Calculate the EVSI
N.fit<-round(seq(min(N.q),max(N.q),length.out=Q))
quantiles<-quantile(as.matrix(beta.ab),prob=c(0.975,0.75,0.5,0.25,0.025))
#Use these to calculate the quantiles of the fitted sigma.X variances
quantiles.N<-matrix(NA,nrow=5,ncol=Q)
for(l in 1:5){
quantiles.N[l,]<-sigma.phi*(N.fit/(N.fit+quantiles[l]))
}
#Calculate the EVSI by rescaling INB.phi
EVSI<-matrix(NA,nrow=5,ncol=Q)
mu.phi<-mean(INB.phi)
for(l in 1:5){
for(k in 1:Q){
sigma.X<-(INB.phi-mu.phi)/sqrt(sigma.phi)*sqrt(quantiles.N[l,k])+mu.phi
EVSI[l,k]<-mean(pmax(sigma.X,0))-max(mean(sigma.X),0)
}
}
if(plot==TRUE){
#Calculate EVPPI
EVPPI<-mean(pmax(INB.phi,0)-max(mean(INB.phi),0))
#Set up different lines to plot
lwd<-c(1,2,3,2,1);lty<-c(3,2,1,2,3)
#Plotting
plot(as.matrix(N.fit),EVSI[1,],ylim=c(min(EVSI),max(EVSI,EVPPI)),
type="l",col="white",
xlab=expression("Sample Size of "~X[N]),
ylab="Economic value",oma=c(0,0,-1,0))
for(i in 1:5){
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points(as.matrix(N.fit),EVSI[i,],type="l",
lwd=lwd[i],lty=lty[i])
}
#Add EVPPI to graphic
abline(h=EVPPI,col="red",lwd=2)
}
return(EVSI)
}
}
D Code for the Ades et al. Example
To give an example of the variance calculation, R code is given below to calculate
the σ2q vector for Exercise 1 in the Ades et al. example. The final line uses the
function above to calculate the EVSI using the estimated σ2q values. The total
computation time for this code is around 7 minutes.
##Ades et al. Model
library(R2OpenBUGS)
library(R2jags)
library(mgcv)
library(MASS)
Adesetal.model<-function(){
for(i in 1:N){
X[,i]~dmnorm(theta.5.cor[1:2],Tau.5.1[1:2,1:2])
}
theta.1~dnorm(10000,1/10^2)
theta.11~dnorm(15000,1/10^2)
theta.2~dnorm(0.1,1/.02^2)
theta.12~dnorm(.08,1/.02^2)
theta.3~dnorm(5.2,1/1^2)
theta.13~dnorm(6.1,1/1^2)
theta.4~dnorm(4000,1/2000^2)
theta.8~dnorm(.25,1/.1^2)
theta.17~dnorm(.20,1/.05^2)
theta.9~dnorm(-.1,1/0.02^2)
theta.18~dnorm(-.1,1/0.02^2)
theta.10~dnorm(.5,1/0.2^2)
theta.19~dnorm(.5,1/0.2^2)
#To give correlated parameters, use multivariate normal dist
#theta.5,theta.14,theta.7,theta.16
theta.5.cor[1:4]~dmnorm(mu[],Tau.5[,])
#theta.6,theta.15
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theta.6.cor[1:2]~dmnorm(mu.6[],Tau.6[,])
#Health Economic Model - effects and costs
e[1]<-(theta.5.cor[1]*theta.6.cor[1]*theta.5.cor[3])+(theta.8*theta.9*theta.10)
e[2]<-(theta.5.cor[2]*theta.6.cor[2]*theta.5.cor[4])+(theta.17*theta.18*theta.19)
c[2]<-(theta.11+theta.12*theta.13*theta.4)
c[1]<-(theta.1+theta.2*theta.3*theta.4)
#Net Benefit with willingness to pay of 100000
NB[1]<-100000*e[1]-c[1]
NB[2]<-100000*e[2]-c[2]
}
#Write Model File
filein.model <- "Adesetal.txt"
write.model(Adesetal.model,filein.model)
#Precision Matrices
sig.5<-0.1
sig.14<-0.1
sig.7<-0.5
sig.16<-1
rho<-0.6
S.5<-matrix(c(sig.5^2,rho*sig.14*sig.5,rho*sig.5*sig.7,rho*sig.5*sig.16,
rho*sig.5*sig.14,sig.14^2,rho*sig.14*sig.7,rho*sig.14*sig.16,
rho*sig.5*sig.7,sig.14*rho*sig.7,sig.7^2,rho*sig.16*sig.7,
rho*sig.5*sig.16,sig.14*rho*sig.16,rho*sig.7*sig.16,sig.16^2),
nrow=4)
sig.6<-0.1
sig.15<-0.05
S.6<-matrix(c(sig.6^2,rho*sig.6*sig.15,
rho*sig.6*sig.15,sig.15^2),
nrow=2)
Tau.5<-solve(S.5)
Tau.6<-solve(S.6)
###Data Precision Matrices
sig.5.X<-0.2
sig.14.X<-0.2
sig.7.X<-1
sig.16.X<-2
S.5.X<-matrix(c(sig.5.X^2,rho*sig.5.X*sig.14.X,rho*sig.5.X*sig.7.X,rho*sig.5.X*sig.16.X,
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rho*sig.5.X*sig.14.X,sig.14.X^2,rho*sig.14.X*sig.7.X,rho*sig.14.X*sig.16.X,
rho*sig.5.X*sig.7.X,rho*sig.7.X*sig.14.X,sig.7.X^2,rho*sig.7.X*sig.16.X,
sig.5.X*sig.16.X*rho,rho*sig.16.X*sig.14.X,rho*sig.16.X*sig.7.X,sig.16.X^2),
nrow=4)
Tau.5.1<-solve(S.5.X[1:2,1:2])
#Data to simulate without any data
data<-list(mu=c(.7,.8,3,3),
Tau.5=Tau.5,
Tau.5.1=Tau.5.1,
mu.6=c(.3,.3),
Tau.6=Tau.6,
X=NA,
N=0)
#Global MCMC parameters
n.chains<-3 #Number of chains for MCMC
n.burnin <- 10000 # Number of burn in iterations
n.thin<-20 #Thinning
#1 million simulations without the data
n.iter <- ceiling(1000000*n.thin/n.chains) + n.burnin
# Choose the parameters in the model to monitor
parameters.to.save <- c("theta.5.cor","NB")
#Use jags to sample from the parameters and find INB.theta
model.theta <- jags(
data = data,
parameters.to.save = parameters.to.save,
model.file = filein.model,
n.chains = n.chains,
n.iter = n.iter,
n.thin = n.thin,
n.burnin = n.burnin,DIC=F)
#Calculate INB.theta
INB.theta<-model.theta$BUGSoutput$sims.list$NB[,2]-model.theta$BUGSoutput$sims.list$NB[,1]
var(INB.theta)
#Generate N.q and phi.q
Q<-50
N.min<-5
N.max<-200
#Spaced in the sqrt.
N.q<-trunc(seq(sqrt(N.min),sqrt(N.max),length.out=Q)^2)
#phi.q is two dimensional
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theta.5<-model.theta$BUGSoutput$sims.list$theta.5.cor[,1]
theta.5.q<-quantile(theta.5,probs=(1:Q/(Q+1)))
theta.14<-model.theta$BUGSoutput$sims.list$theta.5.cor[,2]
theta.14.q<-quantile(theta.14,probs=(1:Q/(Q+1)))
#Reorder phi.q randomly
while(abs(cor(N.q,theta.5.q))>0.001){theta.5.q<-sample(theta.5.q,50,replace=F)}
while(abs(cor(N.q,theta.14.q))>0.001){theta.14.q<-sample(theta.14.q,50,replace=F)}
#PHI FOR THIS EXAMPLE
phi.q<-cbind(theta.5.q,theta.14.q)
sigma.q<-array()
for(i in 1:Q){
#For this loop set the sample size and phi value for generating the data.
N<-N.q[i]
mu<-phi.q[i,]
#Generate X conditional on the specific N.q and phi.q
X<-mvrnorm(N,mu,S.5.X[1:2,1:2])
#For use as data X must be a column matrix
X<-t(as.matrix(X))
#Use X as data in the model
data<-list(mu=c(.7,.8,3,3),
Tau.5=Tau.5,
Tau.5.1=Tau.5.1,
mu.6=c(.3,.3),
Tau.6=Tau.6,
X=X,
N=N)
#Moniter the Net Benefit to calculate its variance
parameters.to.save <- c("NB")
#Use fewer simulations to estimate the posterior variance.
n.iter <- ceiling(10000*n.thin/n.chains) + n.burnin
#Use jags to perform MCMC
model.posterior <- jags(
data = data,
parameters.to.save = parameters.to.save,
model.file = filein.model,
n.chains = n.chains,
n.iter = n.iter,
n.thin = n.thin,
n.burnin = n.burnin,DIC=F)
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#Find posterior distribution for the INB
INB.X<-model.posterior$BUGSoutput$sims.list$NB[,2]-model.posterior$BUGSoutput$sims.list$NB[,1]
#Calculate the posterior variance
sigma.q[i]<-var(INB.X)
}
#Find INB.phi
INB.phi<-gam(INB.theta~te(theta.5,theta.14))$fitted.values
####Calculate the EVSI####
EVSI_theta5_theta14<-calc.evsi.N(INB.phi,INB.theta,sigma.q,N.q)
31
50 100 150 200
10
00
15
00
20
00
25
00
EVSI for different sample sizes for θ5 , θ14
Sample Size of  XN
EV
SI
50 100 150 200
30
00
35
00
40
00
45
00
EVSI for different sample sizes for θ6 , θ15
Sample Size of  XN
EV
SI
50 100 150 200
35
00
40
00
45
00
50
00
EVSI for different sample sizes for θ7 , θ16
Sample Size of  XN
EV
SI
50 100 150 200
45
00
50
00
55
00
60
00
EVSI for different sample sizes for θ5 , θ6 , θ14 and θ15
Sample Size of  XN
EV
SI
50 100 150 200
70
00
75
00
80
00
EVSI for different sample sizes for θ5 , θ6 , θ7 , θ14 , θ15 and θ16
Sample Size of  XN
EV
SI
Figure 4: The EVSI estimate calculated with the posterior median of σ2X (solid
line) along with 75% (dashed line) and 95% (solid line) posterior credible in-
tervals for the BK example; Study 1 (Top Left), Study 2 (Top Right), Study
3 (Middle Left), Study 4 (Middle Right) and Study 5 (Bottom). These are
compared with the nested Monte Carlo estimates (red dots) and the Menzies
estimates (blue crosses). The EVPPI for the parameters targeted by the study
is shown as the horizontal red line.
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